Roche-Spark $4.8B Merger Clears US, UK Regulatory Hurdles
The Federal Trade Commission and the United Kingdom's Competition and Markets Authority on Monday separately cleared Switzerland-based Roche's $4.8 billion offer to take over Philadelphia-based gene therapy company Spark Therapeutics Inc.,...To view the full article, register now.
Already a subscriber? Click here to view full article